OncoMatch/Clinical Trials/NCT05759923
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
Is NCT05759923 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies OATD-02 for advanced ovarian carcinoma.
Treatment: OATD-02 — The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Colorectal Cancer
Disease stage
Required: Stage IV
Metastatic disease required
advanced and/or metastatic colorectal cancer, renal cell cancer, or pancreatic cancer or recurrent serous ovarian cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify